Overview
Sending out an SOS: Best Practices for Returning Patients with SOS/VOD to the Road to Recovery
Grand Rounds Series
Registration is closed for this activity.
Are you prepared to properly diagnose and treat sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD)? SOS/VOD is a consequence certain patients experience secondary to hematopoietic stem cell transplants and some hematologic cancer treatments. To effectively build clinical confidence and knowledge on mitigating VOD/SOS, clinicians can benefit from these live visiting professorship programs (VPPs) led by experts on this often-devastating condition. After participating in these VPPs, hematologists, oncologists, bone marrow transplant physicians, intensivists and hepatologists, should be better able to identify and treat SOS/VOD in a more timely, effective manner.
This activity is intended for hematologists, oncologists, bone marrow transplant physicians, intensivists, hepatologists, oncology nurses and the multidisciplinary healthcare team who are involved in the care of patients with SOS.
SOS/VOD can occur in up to 15% of high-risk patients after hematopoietic stem cell transplant, and almost half of cases present with aggressive disease leading to multiorgan failure with a mortality exceeding 80%. New insights into the pathophysiology, risk factors, diagnostic criteria and management have recently been revealed. To effectively translate expert guidance to practice and build clinician confidence in making an accurate diagnosis and optimizing therapeutic benefit through management of VOD/SOS, clinicians benefit from peer-to-peer exchanges to model best practices and discuss practical strategies to achieve goals. Fortunately, with education, clinicians’ attitudes, knowledge, competence and behavior can evolve. To enable clinicians to deliver a personalized approach to care, ACHL is proposing to create an opportunity for small group learning among hematologists, oncologists, bone marrow transplant physicians, intensivists and hepatologists via live, VPPs. The goal of this education is to build clinical confidence in treatment teams by supporting peer-to-peer learning.
Upon completion of this activity, participants will be able to:
• Describe risk factors, modified diagnostic criteria and newly elucidated pathophysiology of SOS/VOD
• Discuss and apply best practices to facilitate an early diagnosis of SOS/VOD
• Apply clinical evidence to optimize therapeutic decision-making in patients with SOS/VOD
• Describe risk factors, modified diagnostic criteria and newly elucidated pathophysiology of SOS/VOD
• Discuss and apply best practices to facilitate an early diagnosis of SOS/VOD
• Apply clinical evidence to optimize therapeutic decision-making in patients with SOS/VOD
Medical University of South Carolina Children’s Hospital/ Hollings Cancer Center
Charleston , SC USA
Click here to view location map
Charleston , SC USA
Click here to view location map
Supported by an educational grant from Jazz Pharmaceuticals, Inc.
Mitchell S. Cairo, MD
Chief, Pediatric Hematology, Oncology, and Stem Cell Transplantation
Director, Children and Adolescent Cancer and Blood Diseases Center
Director, WMC Cancer Center
Medical and Scientific Director, WMC Cellular and Tissue Engineering Laboratory
Medical Director, WMC Hematotherapy Program
Vice Chairman of Pediatrics
Professor of Pediatrics, Medicine, Pathology, Microbiology
& Immunology and Cell Biology & Anatomy,
Maria Fareri Children’s Hospital
Westchester Medical Center (WMC)
New York Medical College
New York, NY
Chief, Pediatric Hematology, Oncology, and Stem Cell Transplantation
Director, Children and Adolescent Cancer and Blood Diseases Center
Director, WMC Cancer Center
Medical and Scientific Director, WMC Cellular and Tissue Engineering Laboratory
Medical Director, WMC Hematotherapy Program
Vice Chairman of Pediatrics
Professor of Pediatrics, Medicine, Pathology, Microbiology
& Immunology and Cell Biology & Anatomy,
Maria Fareri Children’s Hospital
Westchester Medical Center (WMC)
New York Medical College
New York, NY
Kenneth Cooke, MD
Herman and Walter Samuelson Professor of Oncology
Professor of Oncology
Johns Hopkins Kimmel Cancer Center
Baltimore, MD
Mitchell S. Cairo, MD
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any ineligible companies. All relevant financial relationships have been mitigated prior to this activity.
The following financial relationships have been provided:
Mitchell S. Cairo, MD
Sources of Funding for Research: Jazz Pharmaceuticals
Consulting Agreements: Jazz Pharmaceuticals
Speakers' Bureau: Jazz Pharmaceuticals
Kenneth Cooke, MD
Consultant (occasional): Jazz Pharmaceuticals
Advisory board member: Jazz Pharmaceuticals
Honorarium recipient: Jazz Pharmaceuticals
Research support recipient: Jazz Pharmaceuticals
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: prophylactic ursodiol and defibrotide.
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the ineligible company. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires its speakers to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 60 minutes to complete. To receive credit, learners are required to participate in the live activity and complete the posttest and evaluation onsite or online following the education. A certificate will be immediately available upon completion of the surveys. There is no fee to participate in the activity or for the generation of the certificate. For questions, contact Karen Catino at kcatino@achlcme.org.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this live activity a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
